EACS2023: 406 Comparing lamivudine+dolutegravir and bictegravir/emtricitabine/tenofovir alafenamide in antiretroviral therapy-naïve HIV-infected patients: preliminary results from clinical practice H. Long Guiyang Public Health Clinical Center, Guiyang, China General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: The efficacy and safety of both dolutegravir+lamivudine and bictegravir/emtricitabine/tenofovir alafenamide is well demonstrated in different clinical trials in treatment-naïve therapy. However, real-life data are still lacking. In our study, we tried to investigate and compare the virological outcomes and safety of DTG +3TC versus BIC/FTC/TAF. Method: We performed a prospective, observational, cohort analysis of adult PLHIV who were naïve to antiretroviral therapy and initiated the antiretroviral regimen dolutegravir+lamivudine (DTG+3TC) or tenofovir alafenamide/emtricitabine/bictegravir (TAF/FTC/BIC) from January 2020 and March 2022. This study analyzes the effectiveness, defined as the capability of the treatment to achieve a viral suppression with a viral load <50copies/mL. Moreover, we collected viro-immunological parameters as well as laboratory parameters (changes in weight, lipids, liver function and renal function ) at baseline and after 48 weeks and assessed changes through nonparametric tests. Results: We analyzed 230 patients: 126 starting a DTG+3TC and 104 starting TAF/FTC/BIC. At 48 weeks, the proportion of patients maintaining virological suppression were 88% and 89% in the DTG+3TC group and BIC/FTC/TAF group, respectively. Absolute CD4 counts significantly increased in DTG+3TC and BIC/FTC/TAF groups from baseline to 48 weeks (+92 cells/μL; ;+90.5 cells/μL), respectively. CD4/CD8 increasd 0.23 in DTG+3TC groups and 0.18 in BIC/FTC/TAF groups. Weight gain averaged 1.7kg with DTG+3TC while weight gain averaged 4kg with BIC/FTC/TAF. For creatinine clearance rate, BIC/FTC/TAF group decreased by 20 (-32.9 to -7.6) ml/min,and DTG+3TC group decreased by 10 (-20 to -3.3) ml/min.And no patients discontinued treatment by week 48 due to adverse events. Conclusions: In real practice, both optimization strategies showed high tolerability in antiretroviral therapy-naive patients, there was no difference in virological efficacy between DTG+3TC and BIC/FTC/TAF, our study seems to confirm that BIC/FTC/TAF is associated with an increased risk of weight gain and renal function comparison with DTG+3TC. Further studies are needed to properly assess the matter. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 1 115
RkJQdWJsaXNoZXIy Mzc2ODc=